Pain appears to be more intense in people with neuromyelitis optica spectrum disorder (NMOSD) than those with multiple…
Articles by Marisa Wexler, MS
The investigational anti-CD20 antibody ublituximab effectively depletes B-cells in people with relapsing forms of…
Starting treatment with Ocrevus early can lower almost by half the need for a walking aid in people with relapsing forms…
XRHealth has raised $7 million to expand its telehealth platform, with the goal of providing clinicians and patients with…
The investigational, oral BTK inhibitor SAR442168 can limit the number of new inflammatory brain lesions in…
People with secondary progressive multiple sclerosis (SPMS) who began treatment with Mayzent early and continued its use for years…
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted applications from…
Sanofi will host an online science session to present results of a Phase 2b clinical trial testing the safety…
Treatment with Gilenya (fingolimod) could make people with multiple sclerosis (MS) more vulnerable to the parasitic infection known as…
The Consortium of Multiple Sclerosis Centers (CMSC) and the National Multiple Sclerosis Society have created a new database…
People exposed to secondhand cigarette smoke during adolescence may be more likely to develop multiple sclerosis (MS) later in…
New or worsening headaches are a more common side effect of interferon-beta (IFN-beta) treatment in people with multiple sclerosis (MS)…
Physical exercise can ease fatigue in people with multiple sclerosis (MS) and potentially benefit them in many other ways,…
Truxima, a biosimilar of rituximab, is comparable to the originator therapy in terms of effectiveness and safety for treating …
EHP-101, a cannabidiol-derived investigational therapy being developed by Emerald Health Pharmaceuticals (EHP) to treat multiple sclerosis (MS), is not a…
Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) asking for…
Ponesimod may soon be a new oral therapy for people with relapsing multiple sclerosis (MS) in Europe, and a…
Janssen has submitted an application to the European Medicines Agency (EMA) asking that ponesimod be approved as…
AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active…
New data from Public Health England (PHE) and the U.K. MS Society show that the number of people…
Progressive cognitive decline in patients with multiple sclerosis (MS) may not be as inevitable as previously thought, a study…
The agency in charge of health and social services for Quebec, known as the Institut national d’excellence en santé et…
The experimental BTK inhibitor SAR442168 showed an acceptable safety profile and met its primary endpoint — a significant…
The Multiple Sclerosis Association of America (MSAA) is celebrating 50 years of work and dedication to improving the lives…
Caring for children with multiple sclerosis (MS) can affect the mental health of their mothers over the long term,…
The National Institute for Health Care and Excellence (NICE) in the U.K. issued its final decision, approving the inclusion…
Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS)…
People with multiple sclerosis (MS) who complete training through a method called the modified Story Memory Technique (mSMT)…
Ocrevus (ocrelizumab) has been approved in Scotland as a treatment for early, inflammatory primary progressive multiple sclerosis (PPMS).
The first participant has been dosed in the Phase 2 REPAIR-MS clinical trial examining the effects of CNM-Au8, Clene…